INDICATIONS AND USAGE

CARBAGLU® (carglumic acid) is a Carbamoyl Phosphate Synthetase 1 (CPS1) activator indicated as:

- Adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS). During acute hyperammonemic episodes, concomitant administration of CARBAGLU with other ammonia lowering therapies, such as alternate pathway medications, hemodialysis, and dietary protein restriction, is recommended.

- Maintenance therapy in pediatric and adult patients for the treatment of chronic hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS). During maintenance therapy, the concomitant use of other ammonia lowering therapies and protein restriction may be needed based on plasma ammonia levels.

IMPORTANT SAFETY INFORMATION

- Most common adverse reactions (>9%) are: vomiting, abdominal pain, pyrexia, tonsillitis, anemia, diarrhea, ear infection, infections, nasopharyngitis, hemoglobin decreased, and headache.
### ADDITIONAL TREATMENT GUIDELINES

1. CARBAGLU treatment should be managed by a physician and medical team experienced in metabolic disorders.

2. CARBAGLU should be initiated as soon as the diagnosis of NAGS deficiency is suspected, which may be as soon as at birth.

3. Concomitant administration of CARBAGLU with other ammonia lowering therapies is recommended during acute hyperammonemic episodes.

4. Disperse CARBAGLU tablets in water. Do not swallow whole or crushed. Mix each 200 mg tablet in a minimum of 2.5 mL of water to yield a concentration of 80 mg/mL.

5. CARBAGLU can be taken orally or via a nasogastric tube in pediatric and adult patients or via an oral syringe in pediatric patients.

### IMPORTANT SAFETY INFORMATION

- Most common adverse reactions (>9%) are: vomiting, abdominal pain, pyrexia, tonsillitis, anemia, diarrhea, ear infection, infections, nasopharyngitis, hemoglobin decreased, and headache.

- To report SUSPECTED ADVERSE REACTIONS, contact Recordati Rare Diseases Inc. at 1-888-575-8344, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

### DOSEING AND ADMINISTRATION

<table>
<thead>
<tr>
<th>Patient Type</th>
<th>Recommended Dose</th>
<th>Frequency &amp; Timing</th>
<th>Titration Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute Hyperammonemia Pediatric &amp; Adult Patients</td>
<td>100 mg/kg/day to 250 mg/kg/day</td>
<td>Divide total daily dose into 2 to 4 doses* to be given immediately before meals or feedings</td>
<td>Titrate based on patient’s plasma ammonia level and clinical symptoms</td>
</tr>
<tr>
<td>Maintenance for Chronic Hyperammonemia Pediatric &amp; Adult Patients</td>
<td>10 mg/kg/day to 100 mg/kg/day</td>
<td>Divide total daily dose into 2 to 4 doses* to be given immediately before meals or feedings</td>
<td>Titrate to target normal plasma ammonia level for patient’s age</td>
</tr>
</tbody>
</table>

*Round dose to the nearest 100 mg (i.e., half of a CARBAGLU tablet).

### SAMPLE DOSING GUIDES TO HELP WITH EMERGENCY ORDERING

<table>
<thead>
<tr>
<th>Patient – Weight</th>
<th>Acute initial dose (min/max)</th>
<th>Total daily mg</th>
<th># 200-mg tablets per day</th>
<th>3-day supply for acute hyperammonemic episode # 60-tablet and/or 5-tablet bottles</th>
</tr>
</thead>
<tbody>
<tr>
<td>For Example</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neonate – 3 kg (6.61 lbs)</td>
<td>100 mg/kg</td>
<td>300 mg</td>
<td>1.5 tablets</td>
<td>1 bottle of 5 tablets</td>
</tr>
<tr>
<td></td>
<td>250 mg/kg</td>
<td>750 mg</td>
<td>4 tablets</td>
<td>3 bottles of 5 tablets</td>
</tr>
<tr>
<td>For Example</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Toddler – 10 kg (22.05 lbs)</td>
<td>100 mg/kg</td>
<td>1000 mg</td>
<td>5 tablets</td>
<td>3 bottles of 5 tablets</td>
</tr>
<tr>
<td></td>
<td>250 mg/kg</td>
<td>2500 mg</td>
<td>12.5 tablets</td>
<td>8 bottles of 5 tablets</td>
</tr>
<tr>
<td>For Example</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adult – 60 kg (132.28 lbs)</td>
<td>100 mg/kg</td>
<td>6000 mg</td>
<td>30 tablets</td>
<td>1 bottle of 60 tablets and 6 bottles of 5 tablets</td>
</tr>
<tr>
<td></td>
<td>250 mg/kg</td>
<td>15000 mg</td>
<td>75 tablets</td>
<td>3 bottles of 60 tablets and 9 bottles of 5 tablets</td>
</tr>
</tbody>
</table>

### IMPORTANT SAFETY INFORMATION

- Hyperammonemia: Monitor plasma ammonia level during treatment. Prolonged exposure to elevated plasma ammonia level can result in brain injury or death. Prompt use of all therapies necessary to reduce plasma ammonia level is essential.
EXCLUSIVE DISTRIBUTION THROUGH ACCREDO

Representatives at Accredo Health Group, Inc. are committed to helping you and your patients through the ordering process. CARBAGLU is not available in retail pharmacies.

PATIENT HOME DELIVERY

1. Download the CARBAGLU Prescription & Enrollment Form from the Accredo website (www.accredo.com).
2. Complete the CARBAGLU Prescription & Enrollment Form and fax it to the Accredo specialty pharmacy department at 1-888-454-8488.
3. A CARBAGLU specialty pharmacy representative may call to verify information and determine next steps. In some cases, prior authorization may be necessary.

HOSPITAL ORDERS – EMERGENCY OR INPATIENT

1. Alert your hospital pharmacy that your patient requires CARBAGLU. Send an order for CARBAGLU to your hospital pharmacy and specify whether it is a STAT order (required in 6 hours or less*).
2. Ask your hospital pharmacy to call the wholesale department at Accredo at 1-877-900-9223 to place the order.
3. The wholesale department at Accredo will work with your hospital pharmacy to obtain payment information, establish shipping timelines, and verify the delivery address.
4. The Accredo specialty pharmacy team will follow up in 1-2 days to help set up patient home delivery of CARBAGLU, if applicable.

*Delivery time frame is weather dependent and is not guaranteed.

Questions? Contact a CARBAGLU specialty pharmacy representative at 1-888-454-8860.

FINANCIAL ASSISTANCE PROGRAMS

For patients experiencing financial hardship, Recordati Rare Diseases Inc. supports a Patient Assistance Program and a Co-Pay Assistance Program, administered by Accredo. For more information, call: 1-888-454-8860.
INDICATIONS AND USAGE
CARBAGLU® (carglumic acid) is a Carbamoyl Phosphate Synthetase 1 (CPS1) activator indicated as:

- Adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS). During acute hyperammonemic episodes, concomitant administration of CARBAGLU with other ammonia lowering therapies, such as alternate pathway medications, hemodialysis, and dietary protein restriction, is recommended.

- Maintenance therapy in pediatric and adult patients for the treatment of chronic hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS). During maintenance therapy, the concomitant use of other ammonia lowering therapies and protein restriction may be needed based on plasma ammonia levels.

IMPORTANT SAFETY INFORMATION

- Hyperammonemia: Monitor plasma ammonia level during treatment. Prolonged exposure to elevated plasma ammonia level can result in brain injury or death. Prompt use of all therapies necessary to reduce plasma ammonia level is essential.

- Most common adverse reactions (>9%) are: vomiting, abdominal pain, pyrexia, tonsillitis, anemia, diarrhea, ear infection, infections, nasopharyngitis, hemoglobin decreased, and headache.

- To report SUSPECTED ADVERSE REACTIONS, contact Recordati Rare Diseases Inc. at 1-888-575-8344, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

- Pregnancy: No human data; decreased survival and growth in animal offspring.

- Nursing Mothers: Breastfeeding is not recommended while taking CARBAGLU.

REFERENCE
1. CARBAGLU Prescribing Information. Lebanon, NJ: Recordati Rare Diseases Inc.; 2017.
Acute symptomatic hyperammonemia is a life-threatening emergency.¹ Keep a 5-count bottle of CARBAGLU on hand to allow for immediate treatment. Unopened bottles have up to a 3-year expiry date and must be refrigerated.

IMPORTANT SAFETY INFORMATION

- Hyperammonemia: Monitor plasma ammonia level during treatment. Prolonged exposure to elevated plasma ammonia level can result in brain injury or death. Prompt use of all therapies necessary to reduce plasma ammonia level is essential.

Please see Full Prescribing Information, including Instructions for Use, at the end of this brochure.

VISIT: WWW.CARBAGLU.NET

CARBAGLU is a licensed trademark of Recordati Rare Diseases Inc. © 2017 Recordati Rare Diseases Inc.
CARBAGLU®
(carglumic acid) tablet for oral suspension

INDICATIONS AND USAGE
CARBAGLU is a Carbamoyl Phosphate Synthetase 1 (CPS 1) activator indicated as:
- The treatment of acute hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS). (1.1)
- Maintenance therapy for the treatment of chronic hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS). (1.2)

DOSE AND ADMINISTRATION

Dosing (2.1):
- Acute Hyperammonemia: The recommended initial pediatric and adult dosage is 100 mg/kg/day to 250 mg/kg/day. Titrade based on plasma ammonia level and clinical symptoms.
- Maintenance for chronic hyperammonemia: The recommended pediatric and adult maintenance dosage is 10 mg/kg/day to 100 mg/kg/day. Titrade to target normal plasma ammonia level for age.
- Divide the total daily dose into two to four doses.

Dosage and Administration (2):
- For instructions on administration orally or through a nasogastric tube, see the full prescribing information.

Initial U.S. Approval: 2010

Dosage and Administration (2) 11/2017
Warnings and Precautions (5.1) 11/2017

CURRENT MAJOR CHANGES

DOSAGE FORMS AND STRENGTHS
Tablets for oral suspension: 200 mg, functionally scored

CONTRAINDICATIONS
None. (4)

ADVERSE REACTIONS
Most common adverse reactions (>9%) are: vomiting, abdominal pain, pyrexia, tonsillitis, anemia, diarrhea, ear infection, infections, nasopharyngitis, hemoglobin decreased, and headache (6.1).

WARNINGS AND PRECAUTIONS
Hyperammonemia: Monitor plasma ammonia level during treatment. Prolonged exposure to elevated plasma ammonia level can result in brain injury or death. Prompt use of all therapies necessary to reduce plasma ammonia level is essential. (5.1)

ADVERSE REACTIONS
Most common adverse reactions (>9%):
- Vomiting
- Abdominal pain
- Pyrexia
- Tonsillitis
- Anemia
- Diarrhea
- Ear infection
- Infections
- Nasopharyngitis
- Hemoglobin decreased
- Headache

Full prescribing information: CONTENTS*
1 INDICATIONS AND USAGE
1.1 Acute Hyperammonemia in Patients with NAGS Deficiency
1.2 Chronic Hyperammonemia in Patients with NAGS Deficiency
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dosage
2.2 Preparation and Administration
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Hyperammonemia
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.2 Nursing Mothers
8.3 Pediatric Use
8.4 Geriatric Use
10 OVERDOSAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
14 CLINICAL STUDIES
14.1 Responses of Patients with NAGS Deficiency to Acute and Chronic Treatment
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION

FULL PRESCRIBING INFORMATION

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use CARBAGLU safely and effectively. See full prescribing information for CARBAGLU.

Patients with NAGS Deficiency
- CARBAGLU should be initiated as soon as the diagnosis of NAGS deficiency is suspected, which may be as soon as at birth, and managed by a physician and medical team experienced in metabolic disorders.

Preparation for Oral Administration in Pediatric and Adult Patients
- Add about 2.5 mL of water into a small cup for each CARBAGLU tablet or each ½ CARBAGLU tablet needed for the prescribed dose.
- Add the CARBAGLU tablets to the water in the cup.
- Carefully stir the tablet and water mixture.
- Swallow the mixture immediately. Pieces of the tablet may remain in the cup.
- Rinse the cup with additional water and swallow the mixture immediately. Repeat as needed until no pieces of the tablet are left in the cup.

Preparation for Nasogastric Tube Administration in Pediatric and Adult Patients
For patients who have a nasogastric tube in place, CARBAGLU should be administered as follows:
- Add about 2.5 mL of water into a small cup for each CARBAGLU tablet or each ½ CARBAGLU tablet needed for the prescribed dose.
- Add the CARBAGLU tablets to the water in the cup.
- Carefully stir the tablet and water mixture.
- Draw up the mixture into a catheter-tip syringe.
- Administer the mixture immediately through the nasogastric (NG) tube. Pieces of the tablet may remain in the catheter-tip syringe or NG tube.

Full prescribing information: CONTENTS*

1 INDICATIONS AND USAGE
1.1 Acute Hyperammonemia in Patients with NAGS Deficiency
1.2 Chronic Hyperammonemia in Patients with NAGS Deficiency
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dosage
2.2 Preparation and Administration
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Hyperammonemia
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.2 Nursing Mothers
8.3 Pediatric Use
8.4 Geriatric Use
10 OVERDOSAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
14 CLINICAL STUDIES
14.1 Responses of Patients with NAGS Deficiency to Acute and Chronic Treatment
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.
• Flush immediately with 1 to 2 mL of additional water to clear the NG tube.
• Flush the NG tube again, as needed, until no pieces of the tablet are left in the syringe or NG tube.

Preparation for Oral Administration Using an Oral Syringe in Pediatric Patients
For administration via oral syringe, CARBAGLU should be administered as follows:
• Add about 2.5 mL of water into a small cup for each CARBAGLU tablet or each ½ CARBAGLU tablet needed.
• Add the CARBAGLU tablets to the water in the cup.
• Carefully stir the tablet and water mixture.
• Draw up the mixture in an oral syringe and administer immediately. Pieces of the tablet may remain in the oral syringe.
• Refill the oral syringe with a minimum volume of water (1 to 2 mL) and administer immediately.
• Flush the oral syringe again, as needed, until no pieces of the tablet are left in the syringe.

3 DOSAGE FORMS AND STRENGTHS
CARBAGLU is a white and elongated 200 mg tablet for oral suspension, functionally scored and coded “C” on one side.

4 CONTRAINDICATIONS
None

5 WARNINGS AND PRECAUTIONS
5.1 Hyperammonemia
Any episode of acute symptomatic hyperammonemia should be treated as a life-threatening emergency. Treatment of severe hyperammonemia may require dialysis, preferably hemodialysis and/or hemofiltration, to reduce plasma ammonia concentration. Untreated hyperammonemia can result in brain damage and death, and prompt use of all therapies necessary to reduce plasma ammonia level is essential.

Since hyperammonemia in NAGS deficiency is the result of imbalance between ammonia detoxification capacity and protein catabolism, complete protein restriction during an acute hyperammonemic episode is recommended for no longer than 12 to 36 hours while maximizing caloric supplementation to reverse catabolism. Protein should be reintroduced as early as possible, following improvement of metabolic and clinical abnormalities in this setting. During long-term management, dietary protein restriction should be instituted to maintain blood ammonia level within an acceptable range for age.

Ongoing monitoring of plasma ammonia level, neurological status, growth parameters, protein intake/nutritional status (both during acute hyperammonemic episodes and long-term), and relevant laboratory tests in patients receiving CARBAGLU should be part of evaluating the clinical response to treatment.

6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction scores and coded “C” on one side.

Table 1. Adverse Reactions Reported in CARBAGLU in the retrospective case series (≥9%)

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Number of Patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Vomiting</td>
<td>8 (26)</td>
</tr>
<tr>
<td>- Abdominal pain</td>
<td>4 (17)</td>
</tr>
<tr>
<td>- Pyrexia</td>
<td>4 (17)</td>
</tr>
<tr>
<td>- Tonsillitis</td>
<td>4 (17)</td>
</tr>
<tr>
<td>- Anemia</td>
<td>3 (13)</td>
</tr>
<tr>
<td>- Diarrhea</td>
<td>3 (13)</td>
</tr>
<tr>
<td>- Ear infection</td>
<td>3 (13)</td>
</tr>
<tr>
<td>- Infections</td>
<td>3 (13)</td>
</tr>
<tr>
<td>- Nasopharyngitis</td>
<td>3 (13)</td>
</tr>
<tr>
<td>- Hemoglobin decreased</td>
<td>3 (13)</td>
</tr>
<tr>
<td>- Headache</td>
<td>3 (13)</td>
</tr>
<tr>
<td>- Urticaria</td>
<td>2 (9)</td>
</tr>
<tr>
<td>- Asthenia</td>
<td>2 (9)</td>
</tr>
<tr>
<td>- Hyperhidrosis</td>
<td>2 (9)</td>
</tr>
<tr>
<td>- Influenza</td>
<td>2 (9)</td>
</tr>
<tr>
<td>- Pneumonia</td>
<td>2 (9)</td>
</tr>
<tr>
<td>- Weight decreased</td>
<td>2 (9)</td>
</tr>
<tr>
<td>- Anorexia</td>
<td>2 (9)</td>
</tr>
<tr>
<td>- Somnolence</td>
<td>2 (9)</td>
</tr>
<tr>
<td>- Rash</td>
<td>2 (9)</td>
</tr>
</tbody>
</table>

8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Pregnancy Category C
There are no adequate and well controlled studies or available human data with CARBAGLU in pregnant women. Decreased survival and growth occurred in offspring born to animals that received carglumic acid at a dose approximately 38 times the maximum reported human maintenance dose. Because untreated N-acetylglutamate synthase (NAGS) deficiency results in irreversible neurologic damage and death, women with NAGS must remain on treatment throughout pregnancy.

No effects on embryofetal development were observed in pregnant rats treated with up to 2000 mg/kg/day (approximately 38 times the maximum reported human maintenance dose [100 mg/kg/day] based on AUC [area under the plasma concentration-time curve]) from two weeks prior to mating through organogenesis or in pregnant rabbits treated with up to 1000 mg/kg/day (approximately 6 times the maximum reported human maintenance dose [100 mg/kg/day] based on AUC). In a peri- and post-natal developmental study, female rats received oral carglumic acid from organogenesis through lactation at doses of 500 and 2000 mg/kg/day. Decreased growth of offspring was observed at 500 mg/kg/day and higher (approximately 38 times the maximum reported human maintenance dose [100 mg/kg/day] based on AUC) and reduction in offspring survival during lactation was observed at 2000 mg/kg/day (approximately 38 times the maximum reported human maintenance dose [100 mg/kg/day] based on AUC). No effects on physical and sexual development, learning and memory, or reproductive performance were observed through maturation of the surviving offspring at maternal doses up to 2000 mg/kg/day. The high dose (2000 mg/kg/day) produced maternal toxicity (impaired weight gain and approximately 10% mortality).

8.3 Nursing Mothers
It is not known whether CARBAGLU is excreted in human milk. Carglumic acid is excreted in rat milk, and an increase in mortality and impairment of body weight gain occurred in neonatal rats nursed by mothers receiving carglumic acid. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from CARBAGLU, breast-feeding is not recommended. Treatment is continuous and life-long for NAGS deficiency patients.

8.4 Pediatric Use
The efficacy of CARBAGLU for the treatment of hyperammonemia in patients with NAGS deficiency from birth to adulthood was evaluated in a retrospective review of the clinical course of 23 NAGS deficiency patients who all began CARBAGLU treatment during infancy or childhood. There are no apparent differences in clinical response between adults and pediatric NAGS deficiency patients treated with CARBAGLU. However, data are limited.

8.5 Geriatric Use
CARBAGLU has not been studied in the geriatric population. Therefore, the safety and effectiveness in geriatric patients have not been established.

10 OVERDOSE
One patient treated with 650 mg/kg/day of carglumic acid developed symptoms characterized as a monosodium glutamate intoxication-like syndrome: tachycardia, profuse sweating, increased bronchial secretion, increased body temperature and restlessness. These symptoms resolved upon reduction of dose. Repeated oral dosing of carglumic acid at 2000 mg/kg/day was lethal to most neonatal rats within 2-3 days of treatment. The plasma concentrations that produced lethality were not measured. In adult rats, a single oral administration of carglumic acid was lethal at doses up to 2800 mg/kg (approximately 20 times the maximum starting dose based on AUC).

11 DESCRIPTION
CARBAGLU tablets for oral suspension, contain 200 mg of carglumic acid. Carglumic acid, the active substance, is a Carbamoyl Phosphate Synthetase 1 (CPS 1) activator and is soluble in boiling water, slightly soluble in cold water, and practically insoluble in organic solvents.

Chemically carglumic acid is N-carbamoyl-L-glutamic acid or (2S)-2-(carbamoylamino) pentanedioic acid, with a molecular weight of 190.16.

The structural formula is:

[Chemical structure image]

Molecular Formula: C7H10N2O5

The inactive ingredients of CARBAGLU are croscarmellose sodium, hypromellose, microcrystalline cellulose, silica colloidal anhydrous, sodium lauryl sulfate, sodium stearyl fumarate.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action
Carglumic acid is a synthetic structural analogue of N-acetylglutamate (NAG) which is produced from glutamate and acetyl-CoA in a reaction catalyzed by N-acetylglutamate synthase (NAGS), a mitochondrial liver enzyme. NAG acts as an essential allosteric activator of Carbamoyl Phosphate Synthetase 1 (CPS 1), a mitochondrial liver enzyme which catalyzes the first reaction of the urea cycle. The urea cycle, whose role is the disposition of ammonia, includes a series of biochemical reactions in the liver resulting in the conversion of ammonia into urea, which is then excreted through the urine. Carglumic acid acts as a CPS 1 activator in patients with NAGS deficiency, thereby removing the block in the urea cycle and facilitating ammonia detoxification and urea production.

12.2 Pharmacodynamics
In a retrospective review of the clinical course in 23 patients with NAGS deficiency, carglumic acid reduced plasma ammonia levels within 24 hours when administered with and without concomitant ammonia lowering therapies. No dose response relationship has been identified.

12.3 Pharmacokinetics
The pharmacokinetics of carglumic acid have been studied in healthy male subjects using both radiolabeled and non-radiolabeled carglumic acid.

[Chemical structure image]

Molecular Formula: C7H10N2O5

The inactive ingredients of CARBAGLU are croscarmellose sodium, hypromellose, microcrystalline cellulose, silica colloidal anhydrous, sodium lauryl sulfate, sodium stearyl fumarate.
The median Tmax of CARBAGLU was 3 hours (range: 2 to 4 hours). Absolute bioavailability has not been determined. Distribution The apparent volume of distribution was 2657 L (range: 1616-5797). Protein binding has not been determined. Elimination Metabolism A proportion of carglumic acid may be metabolized by the intestinal bacterial flora. The likely end product of carglumic acid metabolism is carbon dioxide, eliminated through the lungs. Excretion Median value for the terminal half-life was 5.6 hours (range 4.3 to 9.5 hours), the apparent total clearance was 5.7 L/min (range 3.0 to 9.7 L/min), the renal clearance was 230 mL/min (range 204 to 445 mL/min), and the 24-hour urinary excretion was 4.5% of the dose. Following administration of a single radiolabeled oral dose of 100 mg/kg of body weight, 9% of the dose was excreted unchanged in the urine and up to 60% of the dose was excreted unchanged in the feces. Drug Interaction Studies No drug interaction studies have been performed. Based on in vitro studies, CARBAGLU is not an inducer of CYP1A2, CYP2B6, CYP2C, and CYP3A4/5 enzymes, and not an inhibitor of CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, and CYP3A4/5 enzymes.

13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of carglumic acid was assessed in a 2-year carcinogenicity study in rats. Carglumic acid was not tumorigenic at oral doses up to 1000 mg/kg/day (approximately 34 times the maximum reported human maintenance dose [100 mg/kg/day] based on AUC). Carglumic acid was negative in the Ames test, chromosomal aberration assay in human lymphocytes, and the in vivo micronucleus assay in rats.

There were no effects on fertility or reproductive performance in female rats at oral doses up to 2000 mg/kg/day (approximately 38 times the maximum reported human maintenance dose [100 mg/kg/day] based on AUC). In a separate study, mating and fertility were unaffected in male rats at oral doses up to 1000 mg/kg/day (approximately 34 times the maximum reported human maintenance dose [100 mg/kg/day] based on AUC).

14 CLINICAL STUDIES
14.1 Responses of Patients with NAGS Deficiency to Acute and Chronic Treatment The efficacy of CARBAGLU in the treatment of hyperammonemia due to NAGS deficiency was evaluated in a retrospective review of the clinical course of 23 NAGS deficiency patients who received CARBAGLU treatment for a median of 7.9 years (range 0.6 to 20.8 years). Treatment with CARBAGLU was divided in two regimens. For acute treatment, patients received a total daily dose of 100 to 250 mg/kg per day primarily administered in 2 to 4 divided doses for the first few days of treatment. For maintenance treatment, the dosage was reduced over time based upon biochemical and clinical responses. The demographics characteristics of the patient population are shown in Table 2.

Table 2. Baseline Characteristics of the 23 NAGS deficiency patients

<table>
<thead>
<tr>
<th>Gender</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at initiation of CARBAGLU therapy (years)</td>
<td>Mean (SD)</td>
<td>2 (4)</td>
</tr>
<tr>
<td>Age groups at initiation of CARBAGLU therapy</td>
<td>Min-Max</td>
<td>0-13</td>
</tr>
<tr>
<td>&gt;30 days</td>
<td>9 (39%)</td>
<td></td>
</tr>
<tr>
<td>30 days - 12 months</td>
<td>9 (39%)</td>
<td></td>
</tr>
<tr>
<td>&gt;1 - 13 years</td>
<td>5 (22%)</td>
<td></td>
</tr>
<tr>
<td>NAGS gene mutations by DNA testing</td>
<td>Homozygous</td>
<td>14 (61%)</td>
</tr>
<tr>
<td>Heterozygous</td>
<td>4 (17%)</td>
<td></td>
</tr>
<tr>
<td>Not available</td>
<td>5 (22%)</td>
<td></td>
</tr>
<tr>
<td>Patients current treatment status</td>
<td>On-going</td>
<td>18 (78%)</td>
</tr>
<tr>
<td>Discontinued</td>
<td>5 (22%)</td>
<td></td>
</tr>
</tbody>
</table>

The clinical observations in the 23 patient case series were retrospective, unblinded and uncontrolled and preclude any meaningful formal statistical analyses of the data. However, short-term efficacy was evaluated using mean and median change in plasma ammonia levels from baseline to days 1 to 3. Persistence of efficacy was evaluated using mean and median change in plasma ammonia level. Table 3 summarizes the plasma ammonia levels at baseline, days 1 to 3 post-CARBAGLU treatment, and long-term CARBAGLU treatment for 13 evaluable patients. Of the 23 NAGS deficiency patients who received treatment with CARBAGLU, a subset of 13 patients who had documented plasma ammonia levels prior to CARBAGLU treatment and after long-term treatment with CARBAGLU were selected for analysis.

All 13 patients had abnormal ammonia levels at baseline. The overall mean baseline plasma ammonia level was 271 micromol/L. By day 3, normal plasma ammonia levels were attained in patients for whom data were available. Long-term efficacy was measured using the last reported plasma ammonia level for each of the 13 patients analyzed (median length of treatment was 6 years; range 1 to 16 years). The mean and median ammonia levels were 23 micromol/L and 24 micromol/L, respectively, after a mean treatment duration of 8 years.

Table 3. Plasma ammonia levels at baseline and after treatment with CARBAGLU

<table>
<thead>
<tr>
<th>Timepoint (prior to first treatment with CARBAGLU)</th>
<th>Statistics (N = 13)</th>
<th>Ammonia** (micromol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>N</td>
<td>13</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>271 (159)</td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>157</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>72-1428</td>
<td></td>
</tr>
<tr>
<td>Missing Data</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Day 1</td>
<td>N</td>
<td>10</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>181 (358)</td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>85</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>25-1190</td>
<td></td>
</tr>
<tr>
<td>Missing Data</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Day 2</td>
<td>N</td>
<td>8</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>69 (78)</td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>44</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>11-255</td>
<td></td>
</tr>
<tr>
<td>Missing Data</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Day 3</td>
<td>N</td>
<td>5</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>27 (11)</td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>9-34</td>
<td></td>
</tr>
<tr>
<td>Missing Data</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

The mean plasma ammonia level at baseline and the decline that is observed after treatment with CARBAGLU in 13 evaluable patients with NAGS deficiency is illustrated in Figure 1.

Figure 1: Ammonia response for 13 evaluable NAGS deficiency patients at baseline and after treatment with CARBAGLU

16 HOW SUPPLIED/STORAGE AND HANDLING

How Supplied CARBAGLU is a white and elongated 200 mg tablet for oral suspension, functionally scored and coded “C” on one side. CARBAGLU is available in 5 or 60 tablets in a high density polyethylene bottle with child resistant polypropylene cap and desiccant unit.

NDC 52276-312-05 Bottles of 5 tablets
NDC 52276-312-60 Bottles of 60 tablets

Storage Store in the original unopened container at 2 – 8°C (36 – 46°F).

After first opening of the container:
- Do not refrigerate, store at room temperature between 15 – 30°C (59 – 86°F).
- Keep the container tightly closed between openings in order to protect from moisture.
- Write the date of opening on the tablet container.
- Do not use after the expiration date stated on the tablet container.
- Discard one month after first opening.

17 PATIENT COUNSELING INFORMATION

Advises the patient to read the FDA-approved patient labeling (Instructions for Use).

Preparation and Administration
- Disperse CARBAGLU tablets in water. Do not swallow whole or crushed.
- Take CARBAGLU immediately before meals or feedings.
- CARBAGLU tablets dispersed in water can be administered orally or via a nasogastric tube, as described in the Instructions for Use.
Storage
• Store UNOPENED container in a refrigerator at 2 to 8°C (36 to 46°F). After first opening of the container: do not refrigerate, store at room temperature between 15 to 30°C (59 to 86°F). Keep the container tightly closed in order to protect from moisture. Write the date of opening on the tablet container. Discard one month after first opening. Do not use after the expiration date stated on the tablet container.

Lactation
• Advise women not to breast-feed during treatment with CARBAGLU [see Use in Specific Populations (8.3)].

Supplied by:
Orphan Europe SARL
Puteaux, France

Licensed to and Distributed by:
Recordati Rare Diseases Inc.
Lebanon, NJ 08833

For drug or ordering information please call Accredo Health Group Inc., Customer Service at 1-888-454-8860.

Carbaglu® is a licensed trademark of Recordati Rare Diseases Inc.
This product label may have been updated. For the most recent prescribing information, please visit www.recordatirarediseases.com or www.carbaglu.net.
Giving CARBAGLU tablets through a nasogastric (NG) tube:

**Children and Adults**

1. Add about 2.5 mL of water into a small cup for each CARBAGLU tablet, or each ½ CARBAGLU tablet, needed for the prescribed dose. For example, if the prescribed dose is 2 CARBAGLU tablets, add about 5 mL of water into the cup. If the prescribed dose is 2½ CARBAGLU tablets, add about 7.5 mL of water into the cup. Ask your healthcare provider if you are not sure of how much water you should use for the prescribed dose of CARBAGLU.

2. Place the prescribed number of CARBAGLU tablets into the water in the cup.

3. Carefully stir the CARBAGLU tablet and water mixture in the cup to avoid spilling the mixture. CARBAGLU tablets do not dissolve completely in water.

4. Draw up all of the CARBAGLU tablet and water mixture in the cup into a catheter-tip syringe.

5. Connect the catheter-tip syringe to the NG tube.

6. Give the CARBAGLU tablet and water mixture through the NG tube right away.

7. Pieces of the tablet may remain in the catheter-tip syringe or NG tube. Refill the catheter-tip syringe with 1 mL to 2 mL of water and flush the NG tube right away.

8. Repeat step 7 until there are no pieces of the tablet left in the catheter-tip syringe or NG tube.

**How should I store CARBAGLU?**

- **Before opening,** store CARBAGLU in a refrigerator between 36°F to 46°F (2°C to 8°C) in the container it comes in.
- **After opening,** store CARBAGLU at room temperature between 59°F to 86°F (15°C to 30°C). Do not store CARBAGLU in a refrigerator.
  - Keep CARBAGLU tablets in a tightly closed container to protect the tablets from moisture.
  - Write the date the CARBAGLU tablet container is opened on the container label. Throw away any unused tablets one month after opening the tablet container.
  - Do not use CARBAGLU tablets after the expiration date on the tablet container.

**Keep CARBAGLU and all medicines out of the reach of children.**

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

**Distributed by:** Recordati Rare Diseases Inc.

**Issued:** November 2017

*Carbaglu® is a licensed trademark of Recordati Rare Diseases Inc.*

**PP-CBGL-US-0098**